Biomedical data scientists study many types of networks, ranging from those formed by
neurons to those created by molecular interactions. People often criticize these networks as …

Background The Psychopharmacology Algorithm Project at the Harvard South Shore
Program presents evidence-based recommendations considering efficacy, tolerability …

Background To investigate the effects of stepwise pharmacotherapy based on early clinical
decision-making on short-and long-term treatment outcomes in outpatients with depressive …

Objective: To assess the long-term efficacy and safety of aripiprazole as an augmentation
strategy for major depressive disorder (MDD). Data Sources: Ovid MEDLINE, PsycInfo, and …

The REDUCE-IT trial demonstrated that icosapent ethyl, an ethyl ester of eicosapentaenoic
acid (EPA), reduced cardiovascular events in an at-risk population by a substantial degree …

Antidepressant treatment has been evolving and changing since the 1950s following the
discovery of the classic antidepressant treatments including tricyclic antidepressants and …

Introduction Current treatment of major depressive disorder (MDD) warrants critical
reexamination. Initial treatment response rates are modest and drop dramatically after 3 …

Approximately 1 in 20 Canadians are diagnosed with it each year, and it is the second
highest cause of disability worldwide. 1 Nonresponse to treatment is common, with response …

Childhood maltreatment (CM) is a predictor of poor outcome across treatments for major
depressive disorder (MDD), while its potential role as a predictor of differential responses to …

Background Clinical guidelines recommend adding a second drug for patients with major
depressive disorder who have a partial response and switching antidepressants for those …